|
Index | - | P/E | - | EPS (ttm) | -0.16 | Insider Own | - | Shs Outstand | 7.28M | Perf Week | 8.40% |
Market Cap | 51.65M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.74M | Perf Month | -19.32% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 17.10% | Short Float | 0.01% | Perf Quarter | -43.15% |
Sales | 0.49M | P/S | 104.91 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.20 | Perf Half Y | - |
Book/sh | 0.94 | P/B | 7.55 | EPS next Y | - | ROA | - | Target Price | 0.92 | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 5.70 - 22.00 | Perf YTD | -43.43% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -67.73% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 24.56% | ATR | 0.69 |
Employees | - | Current Ratio | - | Sales Q/Q | -72.00% | Oper. Margin | - | RSI (14) | 42.88 | Volatility | 6.80% 5.12% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.00 | Prev Close | 7.10 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 2.97K | Price | 7.10 |
Recom | - | SMA20 | -7.44% | SMA50 | -19.87% | SMA200 | -30.79% | Volume | 0 | Change | 0.00% |
![]() |
|
![]() | ||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia. | ||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite